Tech Company Financing Transactions
DeepCyte Funding Round
DeepCyte secured a $1.5 million Seed funding round on 4/9/2026. Investors included private investors.
Transaction Overview
Company Name
Announced On
4/9/2026
Transaction Type
Venture Equity
Amount
$1,500,000
Round
Seed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
221 W 9th St PMB 427
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Undisclosed
Website
Email Address
Overview
Our mission is to go beyond prediction -- to reveal why drugs damage cells and deliver the mechanistic evidence that guides better decisions -- before any patient is exposed. Our vision is to put the 'why' into every prediction. We are doing so by building Digital Cells, human-first AI models that can predict toxicity and highlight mechanisms behind toxic effects, providing actionable information that can help make drugs safer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Carl Evertsz
Chief Executive Officer
Theodore Alexandrov
Chief Financial Officer
Henry Wong
Chief Operating Officer
Shawn Owens
VP - Bus. Development
Katja Ovchinnikova
VP - Bus. Development
Gina Wallbank
VP - Sales
Jeany Delafiori
Browse more venture capital transactions:
Prev: 4/9/2026: Pipe venture capital transaction
Next: 4/9/2026: Edmund venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs